论文部分内容阅读
目的探讨基因重组人乳头瘤病毒16L1蛋白(HPV16L1)在诊断HPV16感染中的临床应用价值。方法对718例因宫颈病变到该院进行HPV检查的患者采用聚合酶链反应(PCR)法和基因重组HPV16 L1蛋白采用ELISA法检测HPV16 L1抗体,并按照宫颈癌组、尖锐湿疣组、宫颈糜烂组对HPV16 L1抗体阳性及HPV16 DNA阳性进行统计分析。结果宫颈癌组的HPV16 L1抗体水平、HPV16 DNA水平均显著高于尖锐湿疣组、宫颈糜烂组,差异均具有统计学意义(P<0.05);根据阳性临界值判定法则,ELISAHPV16 L1抗体检测法及PCR检查法宫颈癌组的HPV16阳性率分别为45.68%、48.15%均显著高于尖锐湿疣组的11.29%、12.90%及宫颈糜烂组的1.75%、1.95%(P<0.05)。尖锐湿疣组的HPV16 L1抗体水平、HPV16 DNA水平、HPV16阳性检出率显著高于宫颈糜烂组,差异均具有统计学意义(P<0.05)。采用ELISA HPV16 L1抗体检查方法与PCR检测的HPV16阳性率符合率为89.23%(58/65),两种方法检测的一致性检验Kappa值=0.921,两种检测方法具有较高的一致性。结论基因重组人乳头瘤病毒16L1蛋白在诊断HPV16感染具有一定的准确性,对宫颈癌HPV16感染的临床筛查具有一定的推广价值。
Objective To investigate the clinical value of HPV16L1 gene in the diagnosis of HPV16 infection. Methods The HPV16 L1 antibody was detected by polymerase chain reaction (PCR) and gene recombinant HPV16 L1 protein in 718 patients who had HPV test due to cervical lesions. According to the cervical cancer group, genital warts group, cervical erosion Group of HPV16 L1 antibody positive and HPV16 DNA positive for statistical analysis. Results The HPV16 L1 antibody level and HPV16 DNA level in cervical cancer group were significantly higher than those in genital warts group and cervical erosion group (P <0.05). According to the rule of positive critical value, ELISA method of antibody to HPV L1 L1 The positive rates of HPV16 in cervical cancer group were 45.68% and 48.15% respectively, which were significantly higher than those in condyloma acuminatum group (11.29%, 12.90% and 1.75% and 1.95%, respectively). HPV16 L1 antibody level, HPV16 DNA level and HPV16 positive rate in genital warts group were significantly higher than those in cervical erosion group (P <0.05). The coincidence rate of HPV16 L1 antibody detection method and HPV16 positive rate was 89.23% (58/65). The Kappa value of consistency test by two methods was 0.921, and the two methods had high consistency. Conclusion The recombinant human papillomavirus 16L1 protein has a certain accuracy in the diagnosis of HPV16 infection and has certain promotion value for the clinical screening of cervical cancer HPV16 infection.